Rare earths, drugs, ships: US reliance on China is a thorny path

The United States faces critical dependencies on foreign supply chains across several strategic sectors: rare earth metals, pharmaceuticals, and shipbuilding. U.S. Ambassador to China, David Purdue, has characterized this situation as unacceptable, warning that even initiating a move away from these dependencies will be a "thorny path." The Rare Earth Bottleneck The challenge with rare earth elements is particularly acute. While the U.S. possesses domestic deposits, the primary bottleneck lies in the processing, separation, and manufacturing of materials crucial for high-tech industries. Data from the U.S. Geological Survey reveals that from 2021 to 2024, China accounted for 71% of American imports of rare earth compounds and metals. The overall U.S. dependence on imports for this category was projected to reach 67% by 2025. Pharmaceutical Production Shifts East The pharmaceutical sector presents a more complex picture. The U.S. remains a global leader in drug development, but over the past decades, a significant portion of mass drug manufacturing and the production of active pharmaceutical ingredients (APIs) has migrated to Asia. This shift is driven by lower production costs, large specialized industrial clusters, and the gradual globalization of supply chains.